CAR-T showdown: new hope to stop Leukemia's return
NCT ID NCT07441291
Summary
This study compares two approaches for patients with B-cell acute lymphoblastic leukemia (B-ALL) who still show tiny amounts of cancer cells after a stem cell transplant. Researchers will test whether a personalized immune cell therapy (CAR-T) works better than standard chemotherapy plus donor cell infusion to clear these remaining cells and prevent the cancer from coming back. The trial involves 70 patients who will be randomly assigned to receive one of the two treatments and followed for one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, China, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.